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Sima Ramratnam, MDh, Ronald L. Sorkness, PhDh, Benjamin M. Gaston, MDi, Serpil C. Erzurum, MDj,
Suzy A.A. Comhair, PhDj, Ross E. Myers, MDi, Joe Zein, MDj, Mark D. DeBoer, MDa, Anne-Marie Irani, MDk,
Elliot Israel, MDl, Bruce Levy, MDl, Juan Carlos Cardet, MDl, Wanda Phipatanakul, MD, MSl,
Jonathan M. Gaffin, MD, MMscl, Fernando Holguin, MD, MPHd, Merritt L. Fajt, MDd, Shean J. Aujla, MDd,
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What is already known about this topic? Severe asthma has distinct phenotypic features in childhood, but whether the
features of severe asthma are different with age has not been widely studied.
What does this article add to our knowledge? With advancing age, asthma is more prevalent in women than men, and
is associated with higher body mass index and greater airﬂow limitation, but lower markers of Th2 inﬂammation.
How does this study impact current management guidelines? Alternate therapies targeting non-Th2 mechanisms of
inﬂammation need further study in the management of adult patients with severe asthma.
BACKGROUND: The effect of age on asthma severity is poorly
understood.
OBJECTIVES: The objective of this study was to compare the
baseline features of severe and nonsevere asthma in the Severe
Asthma Research Program (SARP) III cohort, and examine in
cross section the effects of age on those features.
METHODS: SARP III is a National Institutes of Health/
National Heart Lung Blood Institute multisite 3-year cohort
study conducted to investigate mechanisms of severe asthma.
The sample included 188 children (111 severe, 77 nonsevere)
and 526 adults (313 severe, 213 nonsevere) characterized for
demographic features, symptoms, health care utilization, lung
function, and inﬂammatory markers compared by age and
severity.
RESULTS: Compared with children with nonsevere asthma,
children with severe asthma had more symptoms and more
historical exacerbations, but no difference in body weight, post-
bronchodilator lung function, or inﬂammatory markers. After
childhood, and increasing with age, the cohort had a higher
proportion of women, less allergen sensitization, and overall
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fewer blood eosinophils. Enrollment of participants with
severe asthma was highest in middle-aged adults, who were
older, more obese, with greater airﬂow limitation and higher
blood eosinophils, but less allergen sensitization than adults
with nonsevere asthma.
CONCLUSIONS: The phenotypic features of asthma differ by
severity and with advancing age. With advancing age, patients
with severe asthma are more obese, have greater airﬂow
limitation, less allergen sensitization, and variable type 2
inﬂammation. Novel mechanisms besides type 2 inﬂammatory
pathways may inform the severe asthma phenotype with
advancing age.  2017 The Authors. Published by Elsevier Inc.
on behalf of the American Academy of Allergy, Asthma &
Immunology. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/). (J Allergy Clin Immunol Pract 2018;6:545-54)
Key words: Severe asthma; Asthma phenotypes
Patients with severe asthma require treatment with high-dose
inhaled corticosteroids plus a second controller to maintain
symptom control or have uncontrolled asthma despite therapy.1
Although these patients are estimated to represent 5% to 10% of
the total asthma population in the United States, they have
frequent exacerbations, impaired quality of life, and account for
more than half of the annual costs of asthma.2 From 2001 to
2012 the National Institutes of Health/National Heart Lung
Blood Institute (NIH/NHLBI) supported the Severe Asthma
Research Program (SARP) I and II cohorts to study mechanisms
differentiating severe from nonsevere asthma.3-7 SARP in-
vestigators characterized severe asthma as a heterogeneous syn-
drome with diverse molecular, biochemical, and cellular
inﬂammatory features and structure-function abnormalities.7
Adults and children with severe asthma were further catego-
rized by unbiased statistical methods into clusters based on dis-
tinguishing clinical features.5,6 Although older age was a
determinant of treatment failure in patients with asthma
participating in the NIH Asthma Clinical Research Network
therapeutic trials, these interventional studies did not target
participants with severe asthma.8 Furthermore, age-related dif-
ferences in the features of asthma were not studied in the original
SARP I and II cohorts.
In November 2012, the NIH/NHLBI formed SARP III, a
network of US investigators and a data coordinating center (DCC)
located at regional academic health centers involved in severe
asthma research. The main objective of SARP III is to advance
understanding of severe asthma through the integration of mech-
anistic studies with detailed phenotypic characterization. To
accomplish this goal, a cohort of adults and children with severe and
nonsevere asthma was recruited for detailed characterization and
enrollment into an observational study. This report highlights the
baseline demographic, clinical, physiologic, and inﬂammatory fea-
tures of participants with severe compared with nonsevere asthma
and how these differences are inﬂuenced by age. The selection of
speciﬁc features to examine with age was exploratory to generate
hypotheses to be tested further in the longitudinal protocol.
METHODS
SARP clinical centers were tasked by NIH/NHLBI to recruit a
sample that included 60% severe asthmatics, 50% women, 30%
non-white minorities, and 25% children. Details of the screening
and enrollment procedures are provided in a consort plot (Figure 1)
and in the Methods section and Tables E1 and E2 in this article’s
Online Repository at www.jacionline.org. Current tobacco smokers
committee from GlaxoSmithkline; has received research support and consultancy
fees from Sanoﬁ-Aventis; has received research support and speaker fees from
Boehringer Ingelheim; receives royalties from Elsevier; and has received speaker
fees from AstraZeneca. A. M. Coverstone has received research and travel support
from the NIH (U10 HL109257); and is employed by Washington University in St
Louis. L. B. Bacharier has received research support from the NIH; has received
consultancy and lecture fees from Aerocrine, GlaxoSmithKline, Genentech/
Novartis, Teva, and Boehringer Ingelheim; has received lecture fees and is on the
scientiﬁc advisory board from Merck; has received consultancy fees from
Cephalon; is on the DBV Technologies data safety monitoring board; has received
lecture fees from AstraZeneca; has received honoraria for CME program devel-
opment from WebMD/Medscape; and is on the advisory boards for Sanoﬁ,
Vectura, and Circassia. N. P. Ly has received research support from Vertex; and
has received lecture fees from Genentech. M. C. Peters has received lecture fees
from Genentech and Amgen. L. C. Denlinger has received research support from
the NIH; has received consultancy fees from GlaxoSmithKline and Sanoﬁ-
Regeneron. R. L. Sorkness has received research support from the NIH. B. M.
Gaston has received research support from the National Institutes of Health
(SARP). S. C. Erzurum has received research support from the NIH; is employed
by Cleveland Clinic; has received travel support from American Board of Internal
Medicine; and is Chair of the ABIM Pulmonary Disease Board. R. E. Myers has
received research support from the NIH/NHLBI. J. Zein has received research
support from Cleveland Clinic. A.-M. Irani has received research and travel
support from the NIH; is on the American Board of Allergy & Immunology; has
received consultancy from Merck and Grifols; has received lecture fees from
Merck and Novartis; and receives royalties from ThermoFisher (Spouse is the
inventor of the tryptase assay). E. Israel has received consultancy fees from
AstraZeneca, Philips Respironics, Regeneron Pharmaceuticals, Bird Rock Bio,
Nuvelution Pharmaceuticals, Vitaeris Inc., and Sanoﬁ; has received consultancy
fees and is on the Data Safety and Monitoring Board for Novartis; has received
travel support from Research in Real Life; has received consultancy fees and
travel support from Teva Specialty Pharmaceuticals; and has received research
support from Genentech, Boehringer Ingelheim, GlaxoSmithKline, Merck,
Sunovion, Teva, and Sanoﬁ. D. T. Mauger has received research support from the
NHLBI. N. N. Jarjour has received research support from the NIH; and has
received consultancy fees from AstraZeneca. The rest of the authors declare that
they have no relevant conﬂicts of interest.
Received for publication December 13, 2016; revised May 18, 2017; accepted for
publication May 19, 2017.
Available online August 31, 2017.
Corresponding author: W. Gerald Teague, MD, Division of Respiratory Medicine,
Allergy, and Immunology, Department of Pediatrics, University of Virginia
School of Medicine, Charlottesville, VA 22908. E-mail: wgt2p@virginia.edu.
2213-2198
 2017 The Authors. Published by Elsevier Inc. on behalf of the American Academy
of Allergy, Asthma & Immunology. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.jaip.2017.05.032
J ALLERGY CLIN IMMUNOL PRACT
MARCH/APRIL 2018
546 TEAGUE ETAL
and those with signiﬁcant past smoking history (>5 pack years if
they were <30 years of age and >10 pack years if they were >30
years of age) were excluded. Participants maintained medications for
asthma as prescribed by their care provider. Study procedures were
approved by the Institution Review Board at each institution and an
independent Data Safety Monitoring Board. All subjects provided
informed consent and/or assent.
Asthma was conﬁrmed based on responsiveness to b-agonist
(12% increase in forced expired volume in 1 second [FEV1] from
baseline post-albuterol, n ¼ 451) or (if <12%), a positive meth-
acholine bronchoprovocation (n ¼ 250). Thirteen enrollees with an
FEV1 <50% predicted, and an albuterol response <12% did not
undergo methacholine bronchoprovocation. Severe asthma was
deﬁned according to a modiﬁcation of the European Respiratory
Society/American Thoracic Society consensus deﬁnition.1 Thresh-
olds for high-dose inhaled corticosteroid therapy were 440 mcg of
ﬂuticasone equivalents per day for children 6-11 years of age and
880 mcg ﬂuticasone equivalents per day for subjects 12 years of
age and older. Enrollees treated with high-dose inhaled corticoste-
roids for at least 6 of the previous 12 months and the 3 months
before enrollment were assigned to the severe subgroup and those
who did not meet criteria for severe asthma were assigned to the
nonsevere subgroup. “Children” were deﬁned as those participants
<18 years of age at enrollment.
Characterization procedures, adapted from SARP I and II,3-6
included history and physical examination, vital signs, height,
weight, and Tanner staging for children, characterization question-
naires, assessment of 1-week (Asthma control quotient, 6-item) and
4-week (Asthma Control Test, Childhood Asthma Control Test)
symptom control, asthma-related quality of life scales (standardized
Asthma Quality of Life Questionnaire and Pediatric Asthma Quality
of Life Questionnaire), spirometry with maximal b-agonist revers-
ibility testing (dose escalation protocol at 180 mcg albuterol
increments up to 720 mcg), sputum induction (age 12 and older),
exhaled nitric oxide (FeNO), and blood for complete blood count,
total IgE, and allergen-speciﬁc IgE. Quality standards for spirometry
were followed at each site, and results audited through the DCC.
Medication adherence was measured by the Medication Adherence
Report Scale.9
Data analysis
These included sex, body mass index (BMI), prevalence of obesity
(deﬁned as a BMI  30 kg/m2 for adults and > 95th percentile for
children), pre- and maximum post-bronchodilator (BD) lung func-
tion and prevalence of airﬂow limitation (FEV1/forced vital capacity
[FVC] ratio  lower limit of normal of the Global Lung Initiative
reference values),10 maximum FEV1 BD response (both as absolute
change and % change in FEV1 % predicted from baseline), preva-
lence of allergen sensitization, total blood eosinophil count, and
FeNO. Allergen sensitization was deﬁned as an elevated IgE (>0.35
IU/mL) to one of 15 allergen-speciﬁc IgE blood tests (Methods
section in this article’s Online Repository at www.jacionline.org).
FIGURE 1. SARP III screening, consort procedures, characterization procedures, and schematic of the longitudinal cohort study. Potential
enrollees who did not complete the initial screening questionnaire are not counted among the 948 who underwent airway physiology
screen testing. Potential enrollees with more than 1 screen failure are also not included. FeNO, Fraction expired nitric oxide; NIH/NHLBI,
National Institutes of Health/National Heart Lung Blood Institute; SARP, Severe Asthma Research Program.
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Multiple sensitization was deﬁned as 4 positive speciﬁc IgE tests,
determined by the median of the number of positive blood allergen
tests in the sample. The criterion for peripheral blood eosinophilia
was 300 cells/mL,11 and for increased FeNO 30 ppb.12,13
The cohort features were stratiﬁed by asthma severity (severe and
nonsevere) and age group (children<18 years and adults18 years).
Nonsevere asthma was classiﬁed as mild intermittent, mild persistent,
and moderate persistent (both treated and not treated with inhaled
corticosteroids; Table E3, available in this article’s Online Repository
at www.jacionline.org). The features of ineligible versus enrolled
participants in the study sample are provided (Table E4, available in
this article’s Online Repository at www.jacionline.org).
Categorical data are presented as count and percentages grouped
according to severe versus nonsevere and tested with the Pearson c2
test. Continuous data with approximately Gaussian distributions are
presented as mean and standard deviation, and differences by
severity tested with a t-test. Continuous data with skewed distri-
butions are presented as median and quartiles and differences by
severity tested with a Wilcoxon rank sum test. Supplemental analyses
with and without 13 participants with (a) FEV1 < 50% predicted,
(b) enrollees with a maximum BD response <12.5% from baseline,
and (c) enrollees who did not undergo methacholine bronchopro-
vocation tests were compared. The analysis results did not differ
when these subgroups were excluded.
The relationship between age of enrollment and speciﬁc outcomes
was modeled using cubic splines with appropriate distribution and
link functions. In conducting the analysis, age at enrollment instead
of duration of asthma was used as a dependent variable because
duration of asthma does not correlate with risk factors for severity
and is limited by recall bias.14 Continuous outcomes with the
Gaussian distribution utilized the normal distribution with identity
link, binary outcomes utilized the binomial distribution with logit
link, and count outcomes utilized the Poisson distribution with
log link. In addition to age, models also included severity and the
interaction between age and severity to determine whether the shape
of the age relationship differed by severity. P values of <.05 indi-
cated statistical signiﬁcance. Whereas the selection of the outcomes
of interest was exploratory and not based on a priori hypotheses, no
adjustment was made for multiple tests. All summary statistics, an-
alyses, and graphs were performed via SAS/STAT and SAS/GRAPH
software, Version 9.4, of the SAS System for Windows, Copyright
2012 SAS Institute, Cary, NC.
RESULTS
Differences between severe and nonsevere asthma
Children
General features. Approximately 26.3% of the cohort were
children <18 years of age (n ¼ 111 severe; n ¼ 77 nonsevere)
(Table I). The percentage of males exceeded females, and more
African American children (42%) were enrolled compared with
adults (25%). Children with severe asthma had more symptoms
and historical exacerbations, lower quality of life, and (by deﬁ-
nition) took more controller medications and prednisone than
children with nonsevere asthma, but were no more obese. There
was no signiﬁcant difference in age at diagnosis of asthma or
duration of asthma by severity in children. Mean medication
adherence scores in children did not differ by asthma severity.
Lung function. Children with severe asthma had greater pre-
BD airﬂow limitation than children with nonsevere asthma, but
post-BD airﬂow limitation was similar in severe and nonsevere
asthma (Table II). The mean post-BD absolute change in
FEV1 % predicted was signiﬁcantly greater in children with
severe asthma.
Inflammatory markers and allergen sensitization. No
inﬂammatory marker, neither blood or sputum eosinophils
nor exhaled NO, was higher in children with severe asthma
(Table III). Likewise, total serum IgE and the degree of allergen
sensitization did not differ in children based on asthma severity.
Adults
General features. Adults with severe (n ¼ 313) and non-
severe (n ¼ 213) asthma had similar proportions of female and
minority participants (Table I). Adults with severe asthma were
signiﬁcantly older, more likely to have a higher BMI, more
symptoms, and had more historical exacerbations, longer
duration of asthma, and lower quality of life despite treatment
with higher doses of corticosteroids. Adherence to treatment
and age at diagnosis did not differ by severity.
Lung function. Adults with severe asthma had greater pre-
and post-BD airﬂow limitation than adults with nonsevere
asthma (Table II). The mean post-BD absolute change in
FEV1 % predicted was signiﬁcantly greater in adults with
severe asthma.
Inflammatory markers and allergen sensitization. Adults
with severe asthma had similar values for total and differential
cell counts in induced sputum compared with adults with
nonsevere asthma, but adults with nonsevere asthma had higher
exhaled NO levels than severe asthma (Table III). Adults with
severe asthma had higher total blood eosinophil counts and a
higher prevalence of blood eosinophilia (>300 cells/mL) than
adults with nonsevere asthma. Although total serum IgE
levels did not differ signiﬁcantly based on asthma severity,
enrollees with severe asthma had a signiﬁcantly lower number
of positive allergen-speciﬁc IgE blood tests.
Effects of age on the features of asthma
Asthma severity. After 18 years of age, the number of
enrollees with severe asthma was higher and peaked in middle age
between 50 and 55 years (Figure 2). In contrast, the number of
enrollees with nonsevere asthma did not change appreciably after
childhood. The distribution by age for adults with severe asthma
differed from those with nonsevere asthma (P ¼ .002).
Sex ratio. Before pubescence the ratio of boys to girls favored
boys, but from young adulthood onward, the ratio of women was
higher than men for both severe and nonsevere asthma
(P < .0001; Figure 3).
BMI and obesity. From childhood to middle age, BMI was
higher regardless of asthma severity, and was lower from 50 years
of age onward (P < .0001; Figure E1, available in this article’s
Online Repository at www.jacionline.org). Accordingly, the
prevalence of obesity followed a similar pattern with advancing
age (P < .0001; Figure 4), which likewise was no different based
on severity.
Lung function. Both the pre- and post-BD FEV1/FVC %
predicted were lower as age increased (P < .05 for both;
Figure E2, A and B, available in this article’s Online Repository
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at www.jacionline.org), but the percentage of enrollees who met
the deﬁnition of pre-BD airﬂow limitation was not different with
age (P ¼ .60; Figure 5, A). In contrast, the percentage of
enrollees with post-BD airﬂow limitation was higher with age
(P < .001; Figure 5, B). The maximum absolute change in FEV1
% predicted post-BD was lower with age (P < .0001; Figure 6).
Inflammatory markers and allergen sensitization.
Whereas peripheral blood eosinophil counts were approximately
50% higher in children than adults, blood eosinophilia was lower
by middle age but then was higher in late-middle-aged enrollees
(P < .0001; Figure 7, A). Removing participants who took oral
prednisone (n ¼ 102; 96 severe, 6 nonsevere) from the analysis
had no effect on differences in blood eosinophilia with age.
Exhaled NO values were signiﬁcantly lower with age (P < .0001;
Figure E3, available in this article’s Online Repository at www.
jacionline.org). Children had signiﬁcantly greater number of
positive allergen-speciﬁc IgE blood tests than adults (P < .0001,
Figure 7, B), and accordingly, serum IgE levels in children were
3- to 4-fold higher than adults (P < .0001; Figure E4, available
in this article’s Online Repository at www.jacionline.org).
Adherence. Adherence to treatment was not different
with age.
Interaction of age and asthma severity on specific
outcomes
The interaction of age and asthma severity was signiﬁcant for
3 outcomes. The absolute BD response and prevalence of
sensitization to 4 or more allergens were both signiﬁcantly lower
with age in severe than in nonsevere asthma. Likewise, although
exhaled FeNO levels were lower with age for the entire sample,
exhaled NO values in severe asthma were relatively ﬂat with age
compared with the sharp decline from 20 to 50 years of age in
FeNO in nonsevere asthma (P < .0001).
DISCUSSION
We report herein on the baseline characteristics of the SARP
III cohort, a unique sample recruited according to prespeciﬁed
demographic features at academic health centers concentrated in
urban settings. Thus the sample is enriched in patients with
severe asthma, women, and non-white minorities. In this report,
we compare the baseline features of severe and nonsevere asthma
TABLE I. Features of the SARP III cohort by age and asthma severity: demographics, anthropometrics, smoking history, asthma control,
quality of life, medication adherence, and treatment
Children (<18 y) Adults
Severe Nonsevere Severe Nonsevere
Sample, n 111 77 313 213
Age at enrollment (y), mean  SD 11.5  2.8 11.6  2.9 49.7  12.8* 44.5  14.6
Female, n (%)† 44 (39.6) 27 (35.1) 210 (67.1) 142 (66.7)
Race/ethnicity, n (%)
Caucasian 39 (35.1) 33 (42.9) 194 (62.0) 142 (66.7)
African American 49 (44.1) 32 (41.6) 85 (27.2) 47 (22.1)
Other 23 (20.7) 12 (15.6) 34 (10.9) 24 (11.3)
Hispanic 17 (15.3) 11 (14.3) 10 (3.2) 9 (4.2)
Non-Hispanic 94 (84.7) 66 (85.7) 303 (96.8) 204 (95.8)
BMI (kg/m2), mean  SD 23.3  6.5 22.3  5.8 33.5  8.5* 31.0  7.9
Obese
BMI  30 (18þ y) or BMI  95th percentile (<18 y), n (%) 42 (37.8) 23 (29.9) 195* (62.1) 96 (45.1)
Smoking history in adults 30 y (pack years), mean  SD n/a n/a 0.9  2.2 0.5  1.5
Asthma symptom control
ACT  19 (12 y), n (%) 29* (72.5) 8 (26.7) 240* (76.7) 90 (42.3)
cACT  19 (age 6-11), n (%) 51 (71.8)* 18 (38.3) n/a n/a
ACQ(6), mean  SD 1.3  0.9* 0.9  0.8 1.9  1.1* 1.1  0.9
Age of asthma diagnosis (y), mean  SD 3.0  2.7 3.2  2.8 20.1  16.5 19.0  15.3
Years since onset of asthma symptoms, mean  SD 8.4  3.4 8.4  3.8 29.7  15.6* 25.4  15.6
Years since asthma diagnosis, mean  SD 9.1  3.2 9.3  3.4 32.3  15.7* 28.1  15.9
Number of exacerbations, mean  SD (past 12 mo) 2.8  2.9* 0.8 1.0 2.3  2.8* 0.6 1.2
Total AQLQ(S) score (12 y), mean  SD n/a n/a 4.6  1.3* 5.5  1.1
Total PAQLQ(S) (age 6-11), mean  SD 4.9  1.3 5.8  1.1 n/a n/a
Number controller medications, median (IQR) 3.0 (2.0, 3.0)* 2.0 (1.0, 2.0) 3.0 (2.0, 4.0)* 2.0 (1.0, 2.0)
Daily oral corticosteroids current, n (%) 15 (13.5)* 1 (1.3) 70 (22.4)* 1 (0.5)
Medication Adherence Report Scale (MARS-5)z, mean  SD 21.9  2.9 21.4  3.7 22.4  2.6* 21.4  3.8
ACQ(6), Asthma control quotient, 6-item; ACT, Asthma Control Test; AQLQ(S), standardized Asthma Quality of Life Questionnaire; BMI, body mass index; cACT, Childhood
Asthma Control Test; IQR, interquartile range; PAQLQ(S), standardized Pediatric Asthma Quality of Life Questionnaire; SARP, Severe Asthma Research Program; SD, standard
deviation.
*P < .05 severe vs nonsevere.
†% per column.
zRange 5-25.9
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in cross section and then study the effects of advancing age and
severity on speciﬁc outcomes. We found that children with
asthma, regardless of severity, were predominately male with
normal body mass and normal lung function, but a relatively
high level of blood eosinophilia and allergen sensitization. By
contrast, adults with asthma, also regardless of severity, were
mostly female, with more obesity and greater airﬂow limitation.
The proportion of enrollees with allergen sensitization was high
at all ages, although it was signiﬁcantly lower in severe asthma by
mid-adulthood. The prevalence of airﬂow limitation was signif-
icantly greater with age, and was accompanied by a lower
maximum BD response. Standard markers of Th2 inﬂammation,
both allergen sensitization and blood eosinophilia, were signiﬁ-
cantly lower after childhood.
These results are comparable with the features of severe
asthma reported in previous characterization studies.2-6,15,16
Consistent among these reports, adults with severe asthma
typically include a greater proportion of women, and have more
symptoms, more exacerbations, and a greater degree of BD-
resistant airﬂow limitation. Generally adults with severe asthma
have relatively less allergen sensitization than their nonsevere
counterparts, whereas sputum and blood eosinophil counts vary
signiﬁcantly between cohorts. The SARP III cohort is most
unique compared with other asthma cohorts in having a
TABLE II. Features of the SARP III cohort by age and asthma severity: lung function and maximum bronchodilator response
Children (<18 y) Adults
Severe Nonsevere Severe Nonsevere
Sample, n 111 77 313 213
Pre-BD FEV1 (% pred.), mean  SD 87.3  17.7* 93.2  14.3 65.8  20.2* 81.8  16.6
Mean Z score  SD† 1.0  1.4* 0.5  1.1 2.3  1.4* 1.3  1.2
Pre-BD FVC (% pred.), mean  SD 101.5  15.6 105.0  13.3 79.1  17.4* 92.5  15.6
Mean Z score  SD 0.1  1.3 0.4  1.1 1.5  1.3* 0.5  1.2
Pre-BD FEV1/FVC (% pred.), mean  SD 85.3  11.1* 88.4  9.6 81.7  13.9* 87.9  10.4
Mean Z score  SD 1.8  1.2* 1.4  1.0 1.9  1.3* 1.4  1.1
Pre-BD FEV1/FVC < LLNz, n (%) 61.0 (55.0)* 31.0 (40.3) 178.0 (56.9)* 86.0 (40.4)
Maximum post-BD FEV1 (% pred.), mean  SD 103.4  17.5 105.6  13.4 77.9  19.7* 92.2  15.5
Mean Z score  SD 0.3  1.4 0.5  1.1 1.5  1.3* 0.5  1.1
Maximum post-BD FEV1/FVC (% pred.), mean  SD 95.1  8.7 96.4  7.4 87.1  12.9* 94.0  9.5
Mean Z score  SD 0.6  1.2 0.4  1.0 1.4  1.3* 0.7  1.1
Maximum post-BD FEV1/FVC < LLN, n (%)x 18.0 (16.2) 13.0 (16.9) 130.0 (41.8)* 39.0 (18.3)
FEV1 BD response (absolute change), mean  SD 16.2  11.0* 12.4  7.8 11.9  7.9* 10.5  7.8
BD, Bronchodilator; FEV1, forced expired volume in 1 second; FVC, forced vital capacity; SARP, Severe Asthma Research Program; SD, standard deviation.
*P < .05 severe vs nonsevere.
†Z scores from reference.10
zLLN, lower limits of normal deﬁned by 1.6 Z scores.
x% expressed per column.
TABLE III. Features of the SARP III cohort by age and asthma severity: markers of inflammation
Children (<18 y) Adults
Severe Nonsevere Severe Nonsevere
Sample, n 111 77 313 213
Sputum differential, n 27 17 241 166
Sputum cell count (cells  104/mL), median (min, max) 77.4 (23.7, 153.1) 61.9 (9.5, 199.8) 97.6 (0.0, 195.3) 82.4 (34.9, 187.0)
Sputum eosinophil %, median (min, max) 1.6 (0.0, 53.7) 1.1 (0.0, 61.4) 0.8 (0.0, 63.9) 0.7 (0.0, 59.4)
Sputum neutrophil %, median (min, max) 53.8 (9.4, 90.1) 40.8 (8.3, 80.3) 51.7 (1.5, 99.8) 55.8 (0.5, 99.3)
FeNO (ppb), median (quartiles) 23.0 (12.0, 46.0) 28.0 (12.0, 49.0) 21.0* (13.0, 37.0) 24.0 (16.0, 43.0)
Expired NO > 30 ppb, n (%)† 40 (36.7) 33 (44.0) 96 (31.1)* 87 (40.8)
Serum IgE, median (quartiles) 465 (164, 1207) 490 (151, 834) 163 (45, 384) 141 (46, 374)
At least 1 of 15 positive blood IgE tests, n (%) 104 (94.5) 67 (89.3) 234 (75.2) 173 (82.0)
Number of positive (of 15) allergen-speciﬁc IgE tests,
median (min, max)
6.0 (3.0, 11.0) 7.0 (3.0, 11.0) 3.0* (0.5, 7.0) 4.0 (2.0, 7.0)
Highly sensitized  4/15 positive allergen tests, n (%) 74 (67.3) 50 (66.7) 115 (37.0)* 101 (47.9)
Blood eosinophils (%), median (quartiles) 5.4 (2.5, 9.0) 5.6 (3.5, 8.3) 3.0 (2.0, 5.7) 3.0 (2.0, 5.0)
Total blood eosinophils (cells/mL), median (quartiles) 324 (162, 514) 359 (208, 575) 228* (134, 399) 189 (111, 320)
Blood eosinophilia 300 cells/mL, n (%) 60 (54.1) 49 (63.6) 120 (38.5)* 60 (28.2)
FeNO, Fraction expired nitric oxide; SARP, Severe Asthma Research Program.
*P < .05, severe vs nonsevere.
†% expressed per column.
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relatively greater prevalence of obesity and lower sputum eosin-
ophils.15,16 These ﬁndings may be attributable to intrinsic
population differences, but also could be due to differences in
recruiting practices by study investigators between Europe and
the United States. For example, participants with severe asthma
in Unbiased Biomarkers in Prediction of Respiratory Disease
Outcomes, a large European characterization study, were
required to have been under the care of a respiratory physician
for at least 6 months preceding enrollment.16 This was not an
inclusion criterion for severe asthma in SARP III, and might
account in part for the differences in the 2 cohorts.
A striking ﬁnding in the SARP III cohort was a complete
reversal of the proportion of males to females after adolescence.
This was the case for enrollees with severe and nonsevere asthma.
This result has been consistently found in other asthma cohort
studies2,15-17 and has been attributed to a greater degree of
bronchial responsiveness in postpubertal females18 and potential
deleterious effects of estrogen and progesterone on lung func-
tion19 and beta adrenergic receptor function.20 Alternatively,
testosterone may confer protective effects on lung function.21 Sex
hormone and lung function changes with puberty will be studied
in the longitudinal SARP III protocol so as to better understand
the marked change in sex ratio from males to females that occurs
after adolescence in asthma.
The prevalence of obesity in the SARP III cohort was higher
from childhood to middle age but then was lower after the ﬁfth
decade of life. Children had signiﬁcant variability in BMI but
overall children were less obese than adults, wherein the preva-
lence of obesity in severe adults was nearly 2-fold higher (62%
adults vs 38% children). Factors that may explain the relatively
high prevalence of obesity in the SARP III sample include the
FIGURE 2. Histograms of enrollee counts and age for (A) severe
and (B) nonsevere asthma. Enrollees <18 years of age are shaded
in light green. Because of prespecified recruiting goals of 25%
children and equal numbers of children between 6-11 years and
12-17 years, comparison of the empirical distributions for severe
and nonsevere asthma was limited to adult enrollees shaded in

















FIGURE 3. Logistic regression curves with cubic splines and
bootstrap confidence limits for the percentage of female partici-
pants by age and asthma severity. The age effect is significant
(P<.0001; likelihood ratio test), but the shapes of the curves with
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FIGURE 4. Logistic regression curves with cubic splines and
bootstrap confidence limits for the percentage of obesity by age
at enrollment and asthma severity. The age effect is significant
(P < .0001; likelihood ratio test), but the shapes of the curves do
not differ by severity (P ¼ ns for age by severity interaction).
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general increase in obesity in the US population and enrichment
of the cohort with urban African Americans, a particularly at-risk
minority group.22,23 Obesity appears to predispose adult women
more than it does men and appears to be at least as important as
an asthma risk factor as the metabolic syndrome, if not more
important.24,25 Understanding of how obesity and metabolic
syndrome affect asthma is broadened by the recent ﬁnding that
metabolic syndrome is associated with more severe asthma but
involves only a subset of obese patients.26
The prevalence of post-BD airﬂow limitation in the cohort
was signiﬁcantly higher with advancing age. Whereas post-BD
airﬂow limitation was no different by severity in children,
airﬂow limitation associated with a lower maximum BD response
was more common among adults with severe asthma. This was
due in part to loss of the maximum BD response, which was
signiﬁcantly lower with advancing age, and the slope of this
relationship was steeper in severe versus nonsevere asthma. Dif-
ferences in lung function with age were highly discordant with
age-related differences in markers of Th2 inﬂammation, which
improved as lung function deteriorated. This discordance is the
basis for our speculation that alternate mechanisms, supple-
mental to Th2 inﬂammation, may favor the progression of
airﬂow limitation with age.
Allergen sensitization, an important phenotypic feature of
both severe and non-severe asthma, likewise was informed
signiﬁcantly by advancing age. The downward slope of the
proportion of enrollees sensitized to 4 or more allergens with
advancing age was particularly steep from childhood to middle
age in adults with severe compared with nonsevere asthma. Older
age per se is associated with a reduction in the prevalence of
allergen sensitization in the general population, both in healthy
individuals and those with respiratory disease.27 Thus a plausible
reason for the lower proportions of adults with allergen sensiti-
zation in the SARP III cohort could be differential recruitment of
more nonallergen sensitized adults compared with children.
Likewise we would also consider heterogeneity of the severe
asthma phenotype, particularly inclusion of a cluster of adult
women identiﬁed in SARP I/II5 and in Europe by Haldar et al28
with relatively low allergen sensitization but troublesome symp-
toms refractory to anti-inﬂammatory therapies. Even though
allergen sensitization is lower with age in severe asthma, most
adults with severe asthma and nonsevere asthma are allergen-
sensitized well into late middle age.
The prevalence of peripheral blood eosinophilia was signiﬁ-
cantly higher in children than adults but was not differentiated by
asthma severity. Although the slope of the prevalence of blood
eosinophilia was sharply downward from childhood to middle age,
it reached a plateau and then rose from late middle age onward.
The relatively low number of enrollees in the sample older than 65
years of age might have skewed this result. Although the overall
downward pattern in blood eosinophilia with age appeared to be





















































FIGURE 5. A, Logistic regression curves and confidence limits for
the percentage of pre-BD airflow limitation by age and asthma
severity. The age effect is not significant (n¼ ns; likelihood ratio
test). B, Logistic regression curves and confidence limits for the
percentage of post-BD airflow limitation by age and asthma
severity. The age effect is significant (P < .0001; likelihood ratio
test), but the slopes of the curves do not differ significantly by
severity (P ¼ ns for age by severity interaction). BD, Bronchodi-
lator; FEV1, forced expired volume in 1 second; FVC, forced vital























FIGURE 6. Linear regression lines and confidence limits for the
absolute change in FEV1% post-BD by age and asthma severity.
The age effect is significant (P < .0001; likelihood ratio test), and
the slopes differ significantly by severity (P ¼ .03; for age by
severity interaction). BD, Bronchodilator; FEV1, forced expired
volume in 1 second.
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this outcome was not signiﬁcant. Because of the relatively low
number of acceptable sputum samples in children, we did not
analyze the effects of advancing age on sputum eosinophilia. A
striking feature of the SARP III cohort is the relatively low
numbers of sputum eosinophils compared with those seen in
severe asthmatics reported in European cohorts.16,29 We have no
ready explanation for this except that it could be attributed to
differences in recruiting practices, treatment, and sputum induc-
tion/quantiﬁcation methods.
In the SARP III cohort, FeNO was highest in young adults
between 20 and 35 years of age, and was relatively higher in
nonsevere than it was in severe asthma. The effects of age on
FeNO compared with peripheral blood eosinophilia were strik-
ingly dissimilar, a result that suggests that factors governing the
level of FeNO in asthma are different from those governing
blood eosinophilia. Although the mechanisms for these differ-
ences are unclear, in trials of anti-IL-5, blood eosinophils were
reduced without impacting FeNO, and in trials of anti-IL4ra
antibodies, FeNO was reduced without decreasing blood
eosinophils.30,31 Mechanisms regulating FeNO include airway
buffering capacity,32 enhanced S-nitrosoglutathione activity,33
and T-helper I inﬂammation.34,35 Other factors that could
have independently affected exhaled NO levels in the cohort
include corticosteroid use and obesity.36-38
In summary, we found signiﬁcant differences in the baseline
phenotypic features of severe and nonsevere asthma in children
and adults. Whereas children with asthma tend to be males with
normal weight and lung function in the context of eosinophilia
and frequent allergen sensitization, adults with asthma have more
obesity and are more heterogeneous with regard to measures of
lung function, eosinophilia, and allergen sensitization. Among
adults with asthma, increasing age is signiﬁcantly associated with
greater airﬂow limitation, a decline and then greater eosinophilia
by late middle age, and less allergen sensitization. Age-related
differences in features affected by asthma severity were limited
to the maximum BD response, allergen sensitization, and FeNO.
The greatest number of enrollees in the SARP III cohort with
severe asthma were in middle age, suggesting that gender effects,
obesity, and novel immune perturbations that occur more
commonly in middle age inform the severe asthma phenotype.
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The Severe Asthma Research Program (SARP) III cohort was
assembled in response to a National Institutes of Health (NIH)
mandate (RFA HL-11-018, June 11, 2010) requesting applica-
tions for clinical centers to establish a severe asthma research
program that outlined speciﬁc recruiting methods. Clinical
centers and a data coordinating center were named and a broad
recruiting process was initiated targeting a sample enriched in
severe asthma (60%) and including 30% minorities, 50%
women, and 25% children. Study coordinators at each clinical
site screened potential enrollees with both severe and nonsevere
asthma by various methods including program notices on the
ClinicalTrials.gov web site, data queries of patients with asthma
receiving care at the respective clinical sites, research databases of
patients available for clinical trials, social media, advertisements
in local media, and archives of patients who had participated
previously in SARP I/II.
Maximum bronchodilator response
The threshold maximum bronchodilator response for entry
into the SARP III cohort was a 12.5% increase in forced
expired volume in 1 second (FEV1) % predicted compared with
the prebronchodilator value. A total of 15 children (8% of the
total) and 33 adults (6% of the total) qualiﬁed according to this
threshold but had <200 mL absolute change in FEV1.
Allergen-specific IgE blood tests
These included Dermatophagoides pteronyssinus D1, Dermato-
phagoides farinae D2, Cat dander e1, Dog dander E5, German
cockroach (Blattella germanica) i6, Alternaria alternata m6,
Cladosporium herbarum m2, Aspergillus fumigatus M3, Timothy
grass (or grass mix) gx2, Short ragweed W1, Common weed mix:
cocklebur, lambs quarter, pigweed, English plantain, Russian
thistle Wx5, Tree mix: oak, elm, maple, willow, cypress Tx4,
Tree mix: box elder, birch, beech, oak, walnut Tx6, Mouse urine
proteins E72, and Rat urine protein E74.
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FIGURE E1. Nonlinear regression curves with cubic splines and
bootstrap confidence limits for body mass index (BMI, kg/m2) by
age and asthma severity. The age effect is significant (P < .0001;
F-test), but the shapes of the curves do not differ significantly by






















































FIGURE E2. A, Nonlinear regression curves with cubic splines and
confidence limits for pre-BD FEV1/FVC % predicted by age and
asthma severity. B, Nonlinear regression curves with cubic splines
and confidence limits for the maximum post-BD FEV1/FVC %
predicted by age and asthma severity. The age effect is significant
(P ¼ .04 and P < .0001) for both pre- and post-BD FEV1/FVC %
predicted, respectively. However, the shapes of the curves for
each plot do not differ significantly by severity (P ¼ ns for age by
severity interaction). BD, Bronchodilator; FEV1, forced expired
volume in 1 second; FVC, forced vital capacity.


















FIGURE E3. Poisson regression curves with cubic splines and
bootstrap confidence intervals for FeNO by age and asthma
severity. The age effect is significant (P < .0001; likelihood ratio
test), and the shapes of the curves differ significantly by severity

















FIGURE E4. Poisson regression curves and cubic splines with
confidence intervals for total serum IgE by age of enrollment and
asthma severity. The age effect is significant (P < .0001; likeli-
hood ratio test), but the shapes of the curves do not differ
significantly by severity (P ¼ ns for age by severity interaction).
TABLE E1. SARP III study cohort: inclusion and exclusion criteria
Inclusion criteria
 Physician diagnosis of asthma
 Age 6 y and older
 Bronchodilator reversibility 12%, or airway hyperresponsiveness
reﬂected by a methacholine PC20  16 mg/mL
Exclusion criteria
 No primary medical caregiver
 Pregnancy (if undergoing methacholine challenge or bronchoscopy)
 Current smoking
 Smoking history >10 pack years or >5 pack years if <30 y of age
 Other nonasthmatic chronic pulmonary disorders
 History of premature birth <35 wk estimated gestational age
 Evidence the participant or family may be unreliable or poorly adherent
to asthma treatment or the study procedures
 Known relocation plans away from the clinical center before study
completion
 Any criterion that places the participant at unnecessary risk according to
the judgment of the principal investigator and/or attending physicians of
record
PC20, Provocation concentration of methacholine to decrease the FEV1 by 20% from
baseline; SARP, Severe Asthma Research Program.
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TABLE E2. SARP III longitudinal protocol schedule of visits and procedures
Base line Steroid response Longitudinal protocol
V1 V2 V3 6 mo
V4
12 mo 18 mo
V5
24 mo 30 mo
V6
36 mo
Scheduling window 14 d 18  3 d 90 d 90 d 90 d 90 d 90 d 90 d
Consent/eligibility X
Questionnaires X X X X X X X X X
PE/VS/BMI/tanner stage X X X X
Spirometry X X X X X X
Max bronchodilator X X X X X X
Methacholine X
Pregnancy test X X X X X X
Sputum induction X X X




BMI, Body mass index; CBC, complete blood count; FeNO, fraction expired nitric oxide; PE, physical examination; SARP, Severe Asthma Research Program; VS, vital signs.
TABLE E3. Proportions of adult and pediatric SARP enrollees by
asthma severity and ICS dose range
SARP phenotype group Adult Pediatric Total








3. Untreated moderate: base FEV1
< 80%, no ICS
23 2 25
4.37 1.06
4. Moderate persistent: base FEV1
< 80%, low-med ICS
74 11 85
14.07 5.85
















Total 526 188 714
ATS, American Thoracic Society; ERS, European Respiratory Society; FEV1, forced
expired volume in 1 second; ICS, inhaled corticosteroid; SARP, Severe Asthma
Research Program.








76 (32) 291 (41)
Female
n (%)




159 (68) 408 (57)
Black
n (%)
39 (17) 213 (30)
Other
n (%)




18 (8) 47 (7)
Non-Hispanic
n (%)
216 (92) 667 (93)
Median age (quartiles) 44 (26, 59) 41 (17, 54)
SARP, Severe Asthma Research Program.
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